Conventional Dose Fludarabine-based Regimens are Effective but have Excessive Toxicity in Elderly Patients with Refractory Chronic Lymphocytic Leukemia

References

• Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. and Schiffer, C.A. (2000) "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia", N. Engl. J. Med. 343, 1750–1757.
   PubMed Web of Science ®Google Scholar
• O'Brien, S., Kantarjian, H., Cortes, J., Beran, M., Koller, C., Giles, F.J., Lerner, S. and Keating, M. (2001) "Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia", J. Clin. Oncol. 19, 1414–1420.
   PubMed Web of Science ®Google Scholar
• Bosch, F., Perales, M., Cobo, F., Esteve, J., Rafel, M., Lopez-Guillermo, A., Ribera, J.M., Campo, E. and Montserrat, E. (1997) "Fludarabine, cyclophosphamide and mitoxantrone therapy in resistant or relapsed chronic lymphocytic leukemia or follicular lymphoma", Blood 90s1, 530a.
   Google Scholar
• Cheson, B.D. (1995) "Infectious and immunosuppressive complications of purine analog therapy", J. Clin. Oncol. 13, 2431–2448.
   PubMed Web of Science ®Google Scholar
• Keating, M.J., Kantarjian, H., O'Brien, S., Koller, C., Talpaz, M., Schachner, J., Childs, C.C., Freireich, E.J. and McCredie, K.B. (1991) "Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia", J. Clin. Oncol. 9, 44–49.
   PubMed Web of Science ®Google Scholar
• Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. and Rai, K.R. (1996) "National Cancer Institutesponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment", Blood 87, 4990–4997.
   PubMed Web of Science ®Google Scholar
• Keating, M.J., Smith, T.L., Lerner, S., O'Brien, S., Robertson, L.E., Kantarjian, H. and Freireich, E.J. (2000) "Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia", Leuk. Lymphoma 37, 71–85.
   PubMed Web of Science ®Google Scholar
• Sorensen, J.M., Vena, D.A., Fallavollita, A., Chun, H.G. and Cheson, B.D. (1997) "Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report", J. Clin. Oncol. 15, 458–465.
   PubMed Web of Science ®Google Scholar
• Bosanquet, A.G. and Bosanquet, M.I. (2000) "Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia", Leukemia 14, 712–715.
   PubMed Web of Science ®Google Scholar
• Zinzani, L.P., Bendandi, M., Magagnoli, M., Albertini, P., Rondelli, D., Stefoni, V., Tani, M. and Tura, S. (2000) "Longterm follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia", Haematologica 85, 1135–1139.
   PubMed Web of Science ®Google Scholar
• Robak, T., Blasinska-Morawiec, M., Blonski, J.Z. and Dmoszynska, A. (1999) "2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia", Leuk. Lymphoma 34, 151–157.
   PubMed Web of Science ®Google Scholar
• Warrell, R.P., Jr and Berman, E. (1986) "Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity", J. Clin. Oncol. 4, 74–79.
   PubMed Web of Science ®Google Scholar
• Cheson, B.D., Vena, D.A., Foss, F.M. and Sorensen, J.M. (1994) "Neurotoxicity of purine analogs: a review", J. Clin. Oncol. 12, a2216–2228.
   PubMed Web of Science ®Google Scholar
• Gonzales, H., Bolgert, F., Camporo, P. and Leblond, V. (1999) "Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP)", Hematol. Cell Ther. 41, 183–186.
   PubMedGoogle Scholar
• Di Raimondo, R., Giustolisi, R.R., Cacciola, E., O'Brien, S., Kantarjian, H., Robertson, L.B. and Keating, M.J. (1993) "Autoimmune hemolytic anemia in chronic lymphocytic leukemia treated by fludarabine", Leuk. Lymphoma 11, 63–69.
   PubMed Web of Science ®Google Scholar
• Marotta, G., Bigazzi, C., Lenoci, M., Tozzi, M., Bocchia, M. and Lauria, F. (2000) "Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy", Hematologica 85, 1268–1270.
   PubMed Web of Science ®Google Scholar
• Sudhoff, T., Arning, M. and Schneider, W. (1997) "Prophylactic strategies to meet infectious complications in fludarabine-treated CLL", Leukemia 11s2, s38
   Google Scholar